

References

I-76

1. Mohammed SI, Eldabe S, Simpson KH, et al. Bolus intrathecal injection of ziconotide (prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) System: a pilot study. *Neuromodulation*. 2013;16(6):576-581.
2. Strigenz T. Ziconotide. *Journal of Pain & Palliative Care Pharmacotherapy*. 2014;28(1):73-74.
3. Mitchell A, Crawford A, Hanley K, et al. Administering ziconotide and monitoring patients treated with ziconotide: Expert opinions. *Pain Management Nursing*. September 2013;14(3):e84-e94.
4. Saulino M, Kim P, Shaw W, et al. Practical considerations and patient selection for intrathecal drug delivery in the management of chronic pain. *Journal of Pain Research*. 2014;7:627–638.
5. Webster LR. The relationship between the mechanisms of action and safety profiles of intrathecal morphine and ziconotide: A review of the literature. *Pain Medicine*. 2015;16(7):1265-1277.
6. Sanford M. Intrathecal Ziconotide: A Review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics. *CNS Drugs*. 2013;27(11):989-1002.
7. Ver Donck A, Branken JH, Puylaert M, Hayek S, Mekhail N, Van Zundert J. Intrathecal drug administration in chronic pain syndromes. *World Institute of Pain*. 2014;14(5):461-476.
8. Brookes ME, Eldabe S, Batterham A. Ziconotide monotherapy: a systematic review of randomised controlled trials. *Current Neuropharmacology*. 2017;15(2):217-231.
9. Webster LR. The relationship between the mechanisms of action and safety profiles of intrathecal morphine and ziconotide: a review of the literature. *Pain Med*. 2015;16:1265-1277.
10. Micromedex®Solutions Compendia. 2018. Ziconotide.
11. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. Ziconotide. 2018.
12. Prialt® (ziconotide) [package insert]. Palo Alto, CA. Jazz Pharmaceuticals, Inc. 2013.